161 related articles for article (PubMed ID: 24854996)
1. Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study.
Curtis GM; Lam SW; Reddy AJ; Bauer SR
Pharmacotherapy; 2014 Aug; 34(8):818-25. PubMed ID: 24854996
[TBL] [Abstract][Full Text] [Related]
2. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism.
Fiumara K; Kucher N; Fanikos J; Goldhaber SZ
Am J Cardiol; 2006 Jan; 97(1):127-9. PubMed ID: 16377297
[TBL] [Abstract][Full Text] [Related]
3. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
4. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism.
Brandt K; McGinn K; Quedado J
Ann Pharmacother; 2015 Jul; 49(7):818-24. PubMed ID: 25857308
[TBL] [Abstract][Full Text] [Related]
6. Systemic thrombolysis for acute pulmonary embolism.
Bartel B
Hosp Pract (1995); 2015; 43(1):22-7. PubMed ID: 25559613
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism.
Islam MS
Adv Exp Med Biol; 2017; 906():67-74. PubMed ID: 27628004
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of thrombolytic agents in the treatment of pulmonary embolism.
Capstick T; Henry MT
Eur Respir J; 2005 Nov; 26(5):864-74. PubMed ID: 16264048
[TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism.
Meyer G; Gisselbrecht M; Diehl JL; Journois D; Sors H
Am J Med; 1998 Dec; 105(6):472-7. PubMed ID: 9870831
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism.
Summers K; Schultheis J; Raiff D; Dahhan T
Ann Pharmacother; 2019 Jul; 53(7):711-715. PubMed ID: 30700101
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: influence on length of hospital stay.
Berghaus TM; Thilo C; Bluethgen A; von Scheidt W; Schwaiblmair M
Adv Ther; 2010 Sep; 27(9):648-54. PubMed ID: 20694805
[TBL] [Abstract][Full Text] [Related]
12. Alteplase for the Treatment of Pulmonary Embolism: A Review.
Peters NA; Paciullo CA
Adv Emerg Nurs J; 2015; 37(4):258-72; quiz E4. PubMed ID: 26509723
[TBL] [Abstract][Full Text] [Related]
13. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.
Konstantinides S; Geibel A; Heusel G; Heinrich F; Kasper W;
N Engl J Med; 2002 Oct; 347(15):1143-50. PubMed ID: 12374874
[TBL] [Abstract][Full Text] [Related]
14. Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase.
Lillyblad MP; Qadri GA; Weise BE; Smith CS; St Hill C; Tierney DM; Melamed RR
J Thromb Thrombolysis; 2022 Nov; 54(4):605-615. PubMed ID: 35320471
[TBL] [Abstract][Full Text] [Related]
15. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks.
Rothschild DP; Goldstein JA; Bowers TR
Catheter Cardiovasc Interv; 2019 Feb; 93(3):506-510. PubMed ID: 30549393
[TBL] [Abstract][Full Text] [Related]
16. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
de Ridder I; den Hertog H; van Gemert M; Dippel D; van der Worp B;
Cerebrovasc Dis; 2013; 35(1):60-3. PubMed ID: 23428998
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for major bleeding in the SEATTLE II trial.
Sadiq I; Goldhaber SZ; Liu PY; Piazza G;
Vasc Med; 2017 Feb; 22(1):44-50. PubMed ID: 27913777
[TBL] [Abstract][Full Text] [Related]
18. Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism.
Igneri LA; Hammer JM
J Pharm Pract; 2020 Feb; 33(1):74-89. PubMed ID: 29673293
[TBL] [Abstract][Full Text] [Related]
19. Characterization of alteplase therapy for presumed or confirmed pulmonary embolism during cardiac arrest.
Peppard SR; Parks AM; Zimmerman J
Am J Health Syst Pharm; 2018 Jun; 75(12):870-875. PubMed ID: 29880524
[TBL] [Abstract][Full Text] [Related]
20. Practice patterns and complication rates of thrombolysis for pulmonary embolism.
Bradford MA; Lindenauer PK; Walkey AJ
J Thromb Thrombolysis; 2016 Oct; 42(3):313-21. PubMed ID: 26961258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
